PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
Provided By GlobeNewswire
Last update: May 9, 2024
30 month median overall survival (OS); median OS independent of patient CPS score
ORR 34% (CPS≥1); 48% (CPS≥20)
Phase 3 registrational trial planned to initiate in 2024
Read more at globenewswire.comNASDAQ:PDSB (4/30/2025, 10:36:38 AM)
1.245
-0.01 (-1.19%)
Find more stocks in the Stock Screener
